All In Biotech

Drug Trial Radar · NCT06731478

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

A Multicenter, Randomized, Open-Label, Phase 3 Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab Versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab as First-Line Treatment in Participants With Unresectable, Locally Advanced or Metastatic HER2-Positive Gastric Or Gastroesophageal Junction (GEJ) Cancer (Destiny-Gastric05)

Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 726 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

726

Planned (sponsor's estimate)

Start

Feb 27, 2025

Primary completion

Jun 1, 2028

Study completion Feb 1, 2030

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Dec 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial is designed to assess the efficacy and safety of the triplet combination of trastuzumab deruxtecan (ENHERTU, T-DXd, DS-8201a) plus a fluoropyrimidine plus pembrolizumab versus standard of care (SoC) chemotherapy plus trastuzumab plus pembrolizumab as first-line therapy in participants with unresectable, locally advanced or metastatic HER2-positive tumor PD-L1 CPS ≥1 gastric or GEJ cancer in the Main Cohort. An Exploratory Cohort will also be evaluated to assess the efficacy and safety of T-DXd plus a fluoropyrimidine versus SoC chemotherapy plus trastuzumab in participants with unresectable, locally advanced or metastatic HER2-positive tumor PD-L1 CPS \<1 gastric or GEJ cancer.

Conditions

  • Gastric Cancer
  • Gastroesophageal Junction Cancer

Interventions

  • Trastuzumab DeruxtecanDrug

    T-DXd will be administered at a dose of 5.4 mg/kg intravenously (IV) every 3 weeks (Q3W)

  • pembrolizumabDrug

    Pembrolizumab will be administered at a dose of 200 mg IV Q3W

  • TrastuzumabDrug

    Trastuzumab will be administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg IV Q3W

  • ChemotherapyDrug

    For Arms M1 and E1: 5-FU or capecitabine will be administered. For Arms M2 and E2: Cisplatin plus 5-FU or oxaliplatin plus capecitabine will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: From date of randomization to the date of radiographic disease progression or death due to any cause, up to 59 months

Locations

250 sites in 26 countries. Site status is shown where the registry gives one.

  • Yale Cancer Center

    New Haven, Connecticut · Not yet recruiting

  • Orchard Healthcare Research Inc.

    Skokie, Illinois · Recruiting

  • University of Kansas Medical Center Research Institute, Inc.

    Kansas City, Kansas · Not yet recruiting

  • Maryland Oncology Hematology, P.A.

    Silver Spring, Maryland · Not yet recruiting

  • Tufts Medical Center

    Boston, Massachusetts · Recruiting

  • University of Michigan Comprehensive Cancer Center Michigan Medicine

    Ann Arbor, Michigan · Recruiting

  • Minnesota Oncology Hematology, P.A.

    Minneapolis, Minnesota · Withdrawn

  • Memorial Sloan Kettering Cancer Center - MAIN

    New York, New York · Recruiting

  • Montefiore Medical Center

    The Bronx, New York · Recruiting

  • Providence Portland Medical Center

    Portland, Oregon · Recruiting

  • Penn State University Milton S. Hershey Medical Center

    Hershey, Pennsylvania · Recruiting

  • Prisma Health Cancer Institute, ITOR, CRU

    Greenville, South Carolina · Recruiting

  • Tennessee Oncology Nashville Midtown

    Nashville, Tennessee · Withdrawn

  • UT Southwestern Medical Center

    Dallas, Texas · Recruiting

  • Texas Oncology, P.A. - Tyler

    Tyler, Texas · Not yet recruiting

  • Virginia Oncology Associates

    Norfolk, Virginia · Not yet recruiting

  • Blue Ridge Cancer Care

    Roanoke, Virginia · Not yet recruiting

  • Wenatchee Valley Hospital & Clinics

    Wenatchee, Washington · Withdrawn

  • CEMIC Ciudad Autonoma

    Buenos Aires, Argentina · Not yet recruiting

  • Instituto Medico Especializado Alexander Fleming

    Buenos Aires, Argentina · Recruiting

  • Clinica Universitaria Privada Reina Fabiola

    Córdoba, Argentina · Recruiting

  • Centro de Investigaciones Medicas Mar del Plata

    Mar del Plata, Argentina · Recruiting

  • Instituto Medico de la Fundacion Estudios Clinicos

    Rosario, Argentina · Recruiting

  • Flinders Medical Centre

    Bedford Park, Australia · Recruiting

  • Monash Medical Centre Clayton

    Clayton, Australia · Recruiting

  • Townsville University Hospital

    Douglas, Australia · Recruiting

  • Peter MacCallum Cancer Centre

    North Melbourne, Australia · Recruiting

  • GenesisCare North Shore (Oncology)

    St Leonards, Australia · Recruiting

  • St John of God Subiaco Hospital

    Subiaco, Australia · Recruiting

  • Wollongong Hospital

    Wollongong, Australia · Recruiting

  • LKH - Universitaetsklinikum Graz

    Graz, Austria · Recruiting

  • Medizinische Universität Innsbruck

    Innsbruck, Austria · Recruiting

  • Medizinische Universität Wien

    Vienna, Austria · Recruiting

  • St. Josef Krankenhaus Wien

    Vienna, Austria · Recruiting

  • Landesklinikum Wiener Neustadt

    Wiener Neustadt, Austria · Recruiting

  • Institut Jules Bordet

    Anderlecht, Belgium · Recruiting

  • AZ Sint-Lucas

    Bruges, Belgium · Recruiting

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium · Recruiting

  • UZ Leuven

    Leuven, Belgium · Recruiting

  • Centre Hospitalier Universitaire de Liege

    Liège, Belgium · Recruiting

Showing 40 of 250 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.